carvedilol has been researched along with Autoimmune Disease in 6 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 7.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "To observe the effects of carvedilol on the expression of Bcl-2, Bax and Fas in autoimmune myocarditis (AM)." | 7.77 | [Effects of carvedilol on cardiomyocyte apoptosis in autoimmune myocarditis in mice]. ( Chen, Q; Jiang, JB; Qiu, HX; Rong, X; Wang, ZQ; Wu, HP; Wu, RZ; Xiang, RL, 2011) |
| "The cardioprotective effects of carvedilol were studied in a rat model of experimental autoimmune myocarditis (EAM)." | 7.76 | Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis. ( Chen, L; Gu, W; Kong, Y; Li, W; Liu, H; Yang, N, 2010) |
| "We investigated whether carvedilol protects against experimental autoimmune myocarditis (EAM) attributing to antioxidant properties." | 7.72 | Cardioprotective effects of carvedilol on acute autoimmune myocarditis. ( Kishimoto, C; Nimata, M; Shioji, K; Yuan, Z, 2004) |
| "Carvedilol in 3 doses (2, 10, and 30 mg/kg) was given daily to 3 study groups of rats (n = 8) with experimental autoimmune myocarditis by gastric gavage for 3 weeks." | 3.88 | Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application. ( Biczysko, W; Ceremuga, I; Dziegiel, P; Haczkiewicz, K; Kobierzycki, C; Kwiatkowska, J; Piasecki, T; Podhorska-Okolow, M; Sapa, A; Skrzypiec-Spring, M; Szelag, A; Wozniak, M, 2018) |
| "To observe the effects of carvedilol on the expression of Bcl-2, Bax and Fas in autoimmune myocarditis (AM)." | 3.77 | [Effects of carvedilol on cardiomyocyte apoptosis in autoimmune myocarditis in mice]. ( Chen, Q; Jiang, JB; Qiu, HX; Rong, X; Wang, ZQ; Wu, HP; Wu, RZ; Xiang, RL, 2011) |
| "The cardioprotective effects of carvedilol were studied in a rat model of experimental autoimmune myocarditis (EAM)." | 3.76 | Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis. ( Chen, L; Gu, W; Kong, Y; Li, W; Liu, H; Yang, N, 2010) |
| "We investigated whether carvedilol protects against experimental autoimmune myocarditis (EAM) attributing to antioxidant properties." | 3.72 | Cardioprotective effects of carvedilol on acute autoimmune myocarditis. ( Kishimoto, C; Nimata, M; Shioji, K; Yuan, Z, 2004) |
| " The cardioprotective properties of carvedilol, a vasodilating beta-adrenoceptor-blocking agent, were studied in a rat model of dilated cardiomyopathy after autoimmune myocarditis." | 3.71 | Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy. ( Aizawa, Y; Ashino, H; Fuse, K; Kodama, M; Nakazawa, M; Takahashi, T; Tanabe, N; Tazawa, S; Wahed, MI; Watanabe, K, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Skrzypiec-Spring, M | 1 |
| Haczkiewicz, K | 1 |
| Sapa, A | 1 |
| Piasecki, T | 1 |
| Kwiatkowska, J | 1 |
| Ceremuga, I | 1 |
| Wozniak, M | 1 |
| Biczysko, W | 1 |
| Kobierzycki, C | 1 |
| Dziegiel, P | 1 |
| Podhorska-Okolow, M | 1 |
| Szelag, A | 1 |
| Liu, H | 1 |
| Li, W | 1 |
| Gu, W | 1 |
| Kong, Y | 1 |
| Yang, N | 1 |
| Chen, L | 1 |
| Wu, RZ | 1 |
| Wu, HP | 1 |
| Wang, ZQ | 1 |
| Rong, X | 1 |
| Jiang, JB | 1 |
| Qiu, HX | 1 |
| Chen, Q | 1 |
| Xiang, RL | 1 |
| Yuan, Z | 2 |
| Shioji, K | 2 |
| Kihara, Y | 1 |
| Takenaka, H | 1 |
| Onozawa, Y | 1 |
| Kishimoto, C | 2 |
| Nimata, M | 1 |
| Watanabe, K | 1 |
| Takahashi, T | 1 |
| Nakazawa, M | 1 |
| Wahed, MI | 1 |
| Fuse, K | 1 |
| Tanabe, N | 1 |
| Kodama, M | 1 |
| Aizawa, Y | 1 |
| Ashino, H | 1 |
| Tazawa, S | 1 |
6 other studies available for carvedilol and Autoimmune Disease
| Article | Year |
|---|---|
Carvedilol Inhibits Matrix Metalloproteinase-2 Activation in Experimental Autoimmune Myocarditis: Possibilities of Cardioprotective Application.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Autoimmune Diseases; Carbazoles; Carvedilol; Di | 2018 |
Immunoregulatory effects of carvedilol on rat experimental autoimmune myocarditis.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Atrial Natriuretic Factor; Autoi | 2010 |
[Effects of carvedilol on cardiomyocyte apoptosis in autoimmune myocarditis in mice].
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Autoimmune Diseases; bcl-2-Associated X Protein; Ca | 2011 |
Cardioprotective effects of carvedilol on acute autoimmune myocarditis: anti-inflammatory effects associated with antioxidant property.
Topics: Acute Disease; Adrenergic beta-Antagonists; Animals; Anti-Inflammatory Agents; Antioxidants; Autoimm | 2004 |
Cardioprotective effects of carvedilol on acute autoimmune myocarditis.
Topics: Administration, Oral; Animals; Autoimmune Diseases; Carbazoles; Cardiotonic Agents; Carvedilol; Dose | 2004 |
Effects of carvedilol on cardiac function and cardiac adrenergic neuronal damage in rats with dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Adrenergic beta-Antagonists; Adrenergic Fibers; Animals; Autoimmune Diseases; | 2002 |